Inhibikase Therapeutics, Inc. (IKT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.50-0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IKT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -26.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IKT — legal / regulatory event — Changes in Registrant’s Certifying Accountant
Dated 2026-08-26
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On August 21, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Inhibikase Therapeutics, Inc. (the “Company”) approved the dismissal of CohnReznick LLP (“CohnReznick”) as the Company’s independent registered public accounting firm, effective immediately. The audit reports of CohnReznick on the Company’s consolidated financial statements for the fiscal year…
Why it matters: Initiating this study is key for IKT-001's development and could impact future growth.
Supportive ifAnnouncement of the Phase 2b study initiation by the end of Q3 2026.
Worry ifNo announcement regarding the Phase 2b study by the end of Q3 2026.
Why it matters: Starting this study is key for IKT-001's development in pulmonary arterial hypertension. It shows progress in their pipeline.
Supportive ifAn official announcement confirming the start of the Phase 2b study for IKT-001.
Worry ifNo announcement or delays in starting the Phase 2b study for IKT-001.
Why it matters: News will show how the designation affects IKT-001's growth and market chance.
Supportive ifLook for new partnerships or funding from the Orphan Drug Designation by Q4 2026.
Worry ifNo new partnerships or funding from the Orphan Drug Designation by Q4 2026.
Why it matters: News on cash reserves will show if the company can fund studies and operations.
Supportive ifCash and equivalents reported above $200 million in Q3 2026.
Worry ifCash and equivalents reported below $150 million in Q3 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$162 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $607 loss on $10,000 · 6.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,683 loss on $10,000 · 26.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Larger losses mean worse financial health. This affects how investors feel and future funding.
Worry ifOperating losses were over $17.8 million for Q2 2026.
Less concerning ifOperating losses were under $17.8 million for Q2 2026.
Why it matters: Data from the ATS conference may change how people see IKT-001's effectiveness and safety.
Watch forPositive feedback or data showing big improvements in PAH markers will be shared on May 17 or 20, 2026.
Also watch forNegative feedback or data showing no big improvements in PAH markers will be shared on May 17 or 20, 2026.
Why it matters: If IKT's revenue growth speeds up, it could signal a positive shift in the business. This would be important as the healthcare sector is slowing down.
Supportive ifIKT reports revenue growth above 10% year over year in the next quarter.
Worry ifRevenue growth remains below 10% year over year.
Why it matters: Enrollment progress is key for the Phase 3 study of IKT-001 in PAH. It shows the study's momentum and potential success.
Supportive ifEnrollment of the first patient in the IMPROVE-PAH study increases to at least 20 patients in the next month.
Worry ifEnrollment stays the same or drops. Fewer than 10 patients may enroll next month.